Nasdaq
$1.43▲ 0.70%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $75.0MShares out 52.5M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
29- 10.6Pre-market26.10.06 20:006-KKey event#●●●#●●●#●●●
OKYO Pharma LtdBullish
OKYO Pharma has announced the enrollment of the first patients in its Phase 3 NEPTUNE trial for urcosimod, a treatment for neuropathic corneal pain (NCP). This multicenter, registrational study is being conducted across the U.S. and Europe to evaluate the efficacy of the drug in accordance with FDA guidance.…more
$1.43+0.70%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 9.29Pre-market26.09.29 20:006-KKey event
OKYO Pharma Ltd
OKYO Pharma announced its participation in upcoming ophthalmic conferences including Eyecelerator, the American Academy of Optometry, and the American Academy of Ophthalmology in October 2026. The company also plans to initiate a global Phase 3 pivotal clinical trial for its NCP treatment, urcosimod, enrolling approximately 111 patients in the second half of this year.…more
$1.43+0.70%vs prev closeView filingShare - 9.9Pre-market26.09.09 20:006-KKey event
OKYO Pharma Ltd
OKYO Pharma will present at the Ophthalmology Futures European Forum on September 10 and the ESCRS iNovation Day on September 11, 2026, to discuss the clinical development of its lead asset, urcosimod. The company aims to engage with the global ophthalmology and investment community regarding the progress of its global Phase 3 pivotal NEPTUNE trial for neuropathic corneal pain.…more
$1.43+0.70%vs prev closeView filingShare
28 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.6Pre-market26.10.06 20:00#●●●#●●●#●●●
OKYO Pharma Initiates Patient Enrollment in Phase 3 Trial for Urcosimod…more
OKYO Pharma has enrolled the first patients in its Phase 3 NEPTUNE trial evaluating urcosimod for the treatment of neuropathic corneal pain. As there are currently no FDA-approved therapies for this condition, this pivotal trial marks a critical step in the company's clinical development program.…more
$1.43+0.70%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 9.29Pre-market26.09.29 20:00
●●●●●●●● ●●●●● ●●●●●●
OKYO Pharma announced its participation and upcoming research presentations at major ophthalmic conferences. While these activities aim to engage industry experts, they do not represent immediate clinical milestones or financial results.…more
$1.43+0.70%vs prev close - 9.8Pre-market26.09.08 20:00
●●●●●●●● ●●●●● ●●●●●●
OKYO Pharma will participate in the Cantor Global Healthcare Conference to engage with investors. The event serves as an opportunity to discuss the company's clinical development plans and future business strategy.…more
$1.43+0.70%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report